American Society of Hirudotherapy

Buccalin-Like Peptide

Putative neuroactive signaling peptide identified in leech salivary tissue — named by analogy to mollusc buccalin; function speculative.

Preclinical / mechanisticLast updated: 2026-05-26 · Reviewed by ASH Editorial Board
Molecular weight of Buccalin-Like Peptide compared with other characterized leech-derived compoundsHementerin80 kDaHementin80 kDaHementin-Like Protein (HLP-1)80 kDaLeech Collagenase70 kDaHaemadipsa yanyuanensis Progr…70 kDaLeech Apyrase67 kDaCalin65 kDaHyaluronidase60 kDaAntithrombin III binding prot…58 kDaCollagenolytic Fibrinolysin55 kDaLeech Thrombospondin-Like Pro…50 kDaBuccalin-Like Peptide1 kDa
Molecular weight (kilodaltons) of Buccalin-Like Peptide (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic
Page type
Compound profile
Evidence type
Putative neuroactive signaling peptide identified in leech salivary tissue — named by analogy to mollusc buccalin; function speculative.
Evidence level
Mechanistic discussion
Drug vs leech
Purified natural compound

Clinical translation limit

This peptide is named by sequence analogy only; biological function in leech is not established. No FDA-approved derivative exists and no clinical efficacy is claimed.

Molecular Profile

Category
Other
Evidence tier
Preclinical
Molecular weight
1,000 Da
Source species
Hirudo medicinalis
Discovered
2018
Buccalin-Like Peptide molecular structure

Biological Targets

  • neuropeptide signaling (mechanism under characterization)

External Resources

    Related Other Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.